Pediatric solid tumors as a model for clinically translating the paradigm of transcriptional addiction in cancer

Dr. Adam Durbin, MD, PhD

Assistant Member, St. Jude Faculty
St. Jude Children’s Research Hospital

Zoom Information: https://mit.zoom.us/j/92098402717
Please turn off your audio and video to save bandwidth.

Dr. Durbin is on staff at Saint Jude's Children's Hospital in Memphis, TN. He is a leader in understanding pediatric solid tumors. Dr. Durbin identified how the transcriptional co-activator EP300 is necessary for neuroblastoma growth. He identified compounds that target P300 for degradation with minimal toxicity profiles and is currently working on their preclinical and clinical development. His work has encompassed a true translational spectrum from super-enhancers to chemotherapeutic regimens for advanced, high-risk pediatric solid tumors. Come hear the latest on management of these deadly malignancies in children and where the gaps remain!

Sponsored by the Center for Precision Cancer Medicine at MIT and the KI Clinical Investigator Program